Skip to main content

Table 1 Pharmacokinetics of TRU-015

From: Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis

Group (mg/kg)

Area under the curve from time 0 to infinity (μg/h/ml)

Maximum concentration of drug (μg/ml)

Half-life (hours)

Coefficient of variability (%)

0.5

1,342

13.8

281

59.1

1.5

7,082

58.2

282

26.5

5

18,140

154

295

33.4

15

71,753

462

409

32.8